Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
— Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®– — PTX-COVID19-B was well tolerated with no safety signals– — Everest is filing IND applications for phase 3 clinical trials for booster indication– SHANGHAI, Oct. 19, 2022 /PRNewswire/ –…
Comments Off on Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults